CCLA Investment Management Increases Holdings in Danaher Corporation $DHR

CCLA Investment Management grew its position in shares of Danaher Corporation (NYSE:DHR) by 41.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 725,976 shares of the conglomerate’s stock after buying an additional 212,337 shares during the quarter. Danaher accounts for approximately 2.3% of CCLA Investment Management’s holdings, making the stock its 15th largest position. CCLA Investment Management owned approximately 0.10% of Danaher worth $143,808,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of DHR. Norges Bank purchased a new position in Danaher in the second quarter worth about $1,979,503,000. Viking Global Investors LP increased its position in shares of Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after purchasing an additional 2,455,994 shares during the last quarter. Generation Investment Management LLP lifted its stake in shares of Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after purchasing an additional 1,787,522 shares during the period. Primecap Management Co. CA boosted its holdings in shares of Danaher by 924.2% in the second quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock worth $244,815,000 after buying an additional 1,118,318 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in shares of Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after buying an additional 1,072,617 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Teri List sold 3,298 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 over the last quarter. Insiders own 11.20% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of a number of research reports. Cowen reaffirmed a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Morgan Stanley assumed coverage on Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 target price on the stock. Barclays boosted their price target on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Finally, The Goldman Sachs Group assumed coverage on Danaher in a research note on Tuesday, December 9th. They issued a “buy” rating and a $265.00 price objective on the stock. Twenty-one equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $248.25.

Danaher Trading Up 0.2%

Shares of DHR stock opened at $224.78 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a fifty day simple moving average of $220.37 and a two-hundred day simple moving average of $207.11. The firm has a market capitalization of $158.77 billion, a PE ratio of 46.35, a PEG ratio of 4.36 and a beta of 0.89. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the company posted $1.71 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.